Show simple item record

dc.contributor.authorHoskin, P
dc.contributor.authorSartor, O
dc.contributor.authorO'Sullivan, J
dc.contributor.authorJohannessen, D
dc.contributor.authorHelle, S
dc.contributor.authorLogue, John P
dc.contributor.authorBottomley, D
dc.contributor.authorNilsson, S
dc.contributor.authorVogelzang, N
dc.contributor.authorFang, F
dc.contributor.authorWahba, M
dc.contributor.authorAksnes, A
dc.contributor.authorParker, C
dc.date.accessioned2015-01-08T16:30:20Z
dc.date.available2015-01-08T16:30:20Z
dc.date.issued2014-11
dc.identifier.citationEfficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. 2014, 15 (12):1397-406 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid25439694
dc.identifier.doi10.1016/S1470-2045(14)70474-7
dc.identifier.urihttp://hdl.handle.net/10541/337972
dc.description.abstractPrimary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases. We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleEfficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.en
dc.typeArticleen
dc.contributor.departmentMount Vernon Cancer Centre, Northwood, Middlesex, UKen
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractPrimary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases. We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223.


Files in this item

This item appears in the following Collection(s)

Show simple item record